President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country's first trade surplus in energy ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...